News & Updates
Filter by Specialty:
Canakinumab improves survival in advanced NSCLC
Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.
Canakinumab improves survival in advanced NSCLC
07 Oct 2023
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
06 Oct 2023
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
Early dipeptidyl peptidase 4 (DPP-4) inhibitor intensification delays insulin initiation in Chinese patients with type 2 diabetes (T2D), a cohort study in Hong Kong has shown.
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
06 Oct 2023
SHBG levels inversely tied to hypertension development
Levels of sex hormone-binding globulin (SHBG) show an inverse relationship with the development of hypertension and change in blood pressure (BP) levels in middle-aged adults, independent of major risk factors, suggests a recent study.